The Pharma Data

JANUARY 18, 2021

His research on understanding the role of angiogenesis and vascular endothelial growth factor (VEGF) in cancer development, led to the discovery that VEGF is a key mediator of angiogenesis associated with intraocular neovascular syndromes. Enquiries: OKYO Pharma Limited. Gary S. Jacob, Chief Executive Officer.

Science 40

Science Virus FDA Approval Treatment 40

NIH Director's Blog: Drug Development

JUNE 14, 2016

The hope is that this teaming of genomic and clinical Big Data will help to streamline the drug development process, helping to avoid late-stage failures attributable to lack of efficacy or adverse safety profiles. 5] Clinical development success rates for investigational drugs. 2014 Jan;32(1):40-51. Novo Nordisk.

Drugs 52

Drugs Disease Drug Development Clinical Trials 52

Drug Discovery World

JULY 13, 2023

There are various schemes in force that allow patients access to unlicensed medicines that are in the late stages of clinical development (i.e., Phases II-III) that address unmet medical needs, usually called expanded access programmes (EAPs), compassionate use programmes (CUPs), or managed access programmes.

Drugs 237

Drugs Licensing Licensing Regulations 237

Drug Discovery World

JANUARY 17, 2024

With oncology accounting for a third of pharma’s product pipeline, significant challenges include fierce competition, high research and development costs over, 10-15 years for clinical development, and pressures to rapidly meet the demand for new treatments 2-4. How long a new drug takes to go through clinical trials.

DNA 147

DNA Clinical Trials RNA Treatment 147

Broad Institute

OCTOBER 11, 2023

As a first step, Manguso set his sights on treatments called PD-1 checkpoint inhibitors, which at the time had shown tremendous promise in clinical trials and would receive their first FDA approval in 2014. Every part of TIDE has been the fruit of collaboration and multidisciplinary team-based science,” Yates said.

Research 137

Research Immune Response Clinical Trials Cell Biology 137

The Pharma Data

AUGUST 17, 2021

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Treatment 52

Treatment Immune Response Trials FDA Approval 52

The Pharma Data

SEPTEMBER 8, 2021

To date, the Opdivo clinical development program has treated more than 35,000 patients. In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Yervoy is approved for unresectable or metastatic melanoma in more than 50 countries.

Research 52

Research Immune Response Treatment Trials 52

The Pharma Data

APRIL 11, 2021

To date, the Opdivo clinical development program has treated more than 35,000 patients. In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Trials 52

Trials Treatment Immune Response Clinical Trials 52

The Pharma Data

JUNE 30, 2021

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Treatment 52

Treatment Trials FDA Approval Disease 52

The Pharma Data

JUNE 26, 2021

There are currently no FDA-approved anticoagulation therapies for pediatric patients with congenital heart disease who have undergone the Fontan procedure, a surgical procedure that redirects blood flow from the lower body to the lungs.

Doctors 52

Doctors Hospitals Clinical Trials Treatment 52

The Pharma Data

MARCH 11, 2021

To date, the Opdivo clinical development program has treated more than 35,000 patients. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Treatment 52

Treatment Trials Therapies FDA Approval 52

The Pharma Data

AUGUST 11, 2020

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Therapies 52

Therapies Trials Disease Treatment 52

The Pharma Data

AUGUST 11, 2020

Opdivo ’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Treatment 52

Treatment Trials Therapies Clinical Trials 52